Tina E Brinkley1, Xiaoyan Leng2, Barbara J Nicklas3, Stephen B Kritchevsky3, Jingzhong Ding3, Dalane W Kitzman4, W Gregory Hundley4. 1. Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC. Electronic address: tbrinkle@wakehealth.edu. 2. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC. 3. Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC. 4. Department of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC.
Abstract
BACKGROUND: Low levels of the soluble receptor for advanced glycation endproducts (sRAGE) have been implicated in a number of chronic diseases. Previous studies indicate that sRAGE levels are ~30% lower in Blacks compared to Whites. However, the reasons for these differences are unclear. PURPOSE: We aimed to identify predictors of circulating sRAGE biomarkers among Black and White adults at high cardiac risk. METHODS: Serum levels of total sRAGE, endogenous secretory RAGE (esRAGE), carboxymethyl-lysine (CML, a major RAGE ligand), and their ratios were measured in 99 Blacks and 454 Whites. RESULTS: Blacks had a more adverse cardiovascular risk profile, as well as lower median levels of total sRAGE (972 vs. 1564pg/ml) and esRAGE (474 vs. 710pg/ml) compared to Whites (p<0.0001). In addition, the proportion of esRAGE was higher in Blacks (47% vs. 44%, p=0.02), as were the CML/total sRAGE (0.89 vs. 0.56ng/pg) and CML/esRAGE (1.72 vs. 1.20ng/pg) ratios (p<0.0001). Racial differences persisted after adjustment for key covariates including age, gender, tobacco use, comorbidities, BMI, blood pressure, glucose, insulin, triglycerides, C-reactive protein, and renal function (p<0.05). Race alone accounted for nearly half of the variability in total sRAGE levels (10.6%; model explained 23.9%). In stratified analyses, gender and heart rate were independently associated with total sRAGE and esRAGE in Whites, while CML and C-reactive protein were associated with total sRAGE in Blacks. CONCLUSIONS: We identified several independent predictors of sRAGE biomarkers. Notably, Black race was associated with an adverse AGE/RAGE profile, including lower sRAGE and higher CML/sRAGE ratios.
BACKGROUND: Low levels of the soluble receptor for advanced glycation endproducts (sRAGE) have been implicated in a number of chronic diseases. Previous studies indicate that sRAGE levels are ~30% lower in Blacks compared to Whites. However, the reasons for these differences are unclear. PURPOSE: We aimed to identify predictors of circulating sRAGE biomarkers among Black and White adults at high cardiac risk. METHODS: Serum levels of total sRAGE, endogenous secretory RAGE (esRAGE), carboxymethyl-lysine (CML, a major RAGE ligand), and their ratios were measured in 99 Blacks and 454 Whites. RESULTS: Blacks had a more adverse cardiovascular risk profile, as well as lower median levels of total sRAGE (972 vs. 1564pg/ml) and esRAGE (474 vs. 710pg/ml) compared to Whites (p<0.0001). In addition, the proportion of esRAGE was higher in Blacks (47% vs. 44%, p=0.02), as were the CML/total sRAGE (0.89 vs. 0.56ng/pg) and CML/esRAGE (1.72 vs. 1.20ng/pg) ratios (p<0.0001). Racial differences persisted after adjustment for key covariates including age, gender, tobacco use, comorbidities, BMI, blood pressure, glucose, insulin, triglycerides, C-reactive protein, and renal function (p<0.05). Race alone accounted for nearly half of the variability in total sRAGE levels (10.6%; model explained 23.9%). In stratified analyses, gender and heart rate were independently associated with total sRAGE and esRAGE in Whites, while CML and C-reactive protein were associated with total sRAGE in Blacks. CONCLUSIONS: We identified several independent predictors of sRAGE biomarkers. Notably, Black race was associated with an adverse AGE/RAGE profile, including lower sRAGE and higher CML/sRAGE ratios.
Authors: Haroon L Chughtai; Timothy M Morgan; Michael Rocco; Brandon Stacey; Tina E Brinkley; Jingzhong Ding; Barbara Nicklas; Craig Hamilton; W Gregory Hundley Journal: Hypertension Date: 2010-09-13 Impact factor: 10.190
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Barry I Hudson; Angela M Carter; Evis Harja; Anastasia Z Kalea; Maria Arriero; Hojin Yang; Peter J Grant; Ann Marie Schmidt Journal: FASEB J Date: 2007-12-18 Impact factor: 5.191
Authors: Eddie Hackler; Jeanney Lew; M Odette Gore; Colby R Ayers; Dorothee Atzler; Amit Khera; Anand Rohatgi; Alana Lewis; Ian Neeland; Torbjorn Omland; James A de Lemos Journal: J Am Heart Assoc Date: 2019-09-13 Impact factor: 5.501
Authors: Run Du; Rui Yan Zhang; Lin Lu; Ying Shen; Li Jin Pu; Zheng Bin Zhu; Qi Zhang; Jian Hu; Zhen Kun Yang; Feng Hua Ding; Jian Sheng Zhang; Wei Feng Shen Journal: Cardiovasc Diabetol Date: 2018-11-27 Impact factor: 9.951
Authors: Amelia K Fotheringham; Jonatan I Bagger; Danielle J Borg; Domenica A McCarthy; Jens J Holst; Tina Vilsbøll; Filip K Knop; Josephine M Forbes Journal: Nutrients Date: 2020-09-24 Impact factor: 5.717